Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration
Rhythm Pharmaceuticals (RYTM) and the Raymond A. Wood Foundation have announced a research collaboration to study the impact of fatigue in people with craniopharyngioma. The initiative involves a registry study open to all diagnosed patients and their caregivers.
The study aims to investigate fatigue effects related to craniopharyngiomas and explore factors like weight gain and daytime sleepiness that may influence patient experiences. Participants can enroll through the Hypothalamic-Pituitary Brain Tumors Patient Registry at the foundation's website.
Rhythm Pharmaceuticals (RYTM) e la Raymond A. Wood Foundation hanno annunciato una collaborazione di ricerca per studiare l'impatto della fatica nelle persone affette da craniopharyngioma. L'iniziativa prevede uno studio registrato aperto a tutti i pazienti diagnosticati e ai loro caregiver.
Lo studio mira a indagare gli effetti della fatica legati ai craniopharyngiomi ed esplorare fattori come l'aumento di peso e la sonnolenza diurna che possono influenzare le esperienze dei pazienti. I partecipanti possono iscriversi attraverso il Registro dei Pazienti con Tumori Ipotalamo-Ipofisari sul sito web della fondazione.
Rhythm Pharmaceuticals (RYTM) y la Fundación Raymond A. Wood han anunciado una colaboración de investigación para estudiar el impacto de la fatiga en personas con craniopharyngioma. La iniciativa implica un estudio de registro abierto a todos los pacientes diagnosticados y sus cuidadores.
El estudio tiene como objetivo investigar los efectos de la fatiga relacionados con los craniopharyngiomas y explorar factores como el aumento de peso y la somnolencia diurna que pueden influir en las experiencias de los pacientes. Los participantes pueden inscribirse a través del Registro de Pacientes con Tumores Hipotalámico-Hipofisarios en el sitio web de la fundación.
리듬 제약 (RYTM)과 레이몬드 A. 우드 재단이 뇌하수체 기형 환자의 피로 영향에 대한 연구 협력을 발표했습니다. 이 이니셔티브는 진단받은 모든 환자와 그들의 보호자를 위한 등록 연구를 포함합니다.
이 연구는 크라니오파린지오마와 관련된 피로의 영향을 조사하고, 환자의 경험에 영향을 미칠 수 있는 체중 증가 및 주간 졸림과 같은 요인을 탐색하는 것을 목표로 합니다. 참가자는 재단 웹사이트의 시상하수체 뇌종양 환자 등록부를 통해 등록할 수 있습니다.
Rhythm Pharmaceuticals (RYTM) et la Fondation Raymond A. Wood ont annoncé une collaboration de recherche pour étudier l'impact de la fatigue chez les personnes atteintes de craniopharyngiome. L'initiative implique une étude de registre ouverte à tous les patients diagnostiqués et à leurs aidants.
Cette étude vise à examiner les effets de la fatigue liés aux craniopharyngiomes et à explorer des facteurs tels que la prise de poids et la somnolence diurne qui peuvent influencer les expériences des patients. Les participants peuvent s'inscrire via le Registre des Patients atteints de Tumeurs Hypothalamo-Hypophysaires sur le site Web de la fondation.
Rhythm Pharmaceuticals (RYTM) und die Raymond A. Wood Stiftung haben eine Forschungskooperation angekündigt, um die Auswirkungen von Müdigkeit bei Menschen mit Kraniopharyngeom zu untersuchen. Die Initiative umfasst eine Registerstudie, die allen diagnostizierten Patienten und ihren Betreuern offensteht.
Die Studie zielt darauf ab, die Auswirkungen von Müdigkeit im Zusammenhang mit Kraniopharyngeom zu untersuchen und Faktoren wie Gewichtszunahme und Tagesmüdigkeit zu erforschen, die die Erfahrungen der Patienten beeinflussen können. Teilnehmer können sich über das Hypothalamisch-Hypophysäre Tumor-Patientenregister auf der Website der Stiftung anmelden.
- None.
- None.
New registry study to focus on impact of fatigue in people with craniopharyngioma
BOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, and the Raymond A. Wood Foundation, a patient advocacy organization for survivors of craniopharyngioma and hypothalamic-pituitary brain tumors, today announced a new research collaboration to study the impact of fatigue on persons with craniopharyngioma.
“We are excited to partner with the Raymond A. Wood Foundation on this survey to learn more about fatigue and its effects related to craniopharyngiomas,” said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm. “Learning directly from patients and caregivers is important to advancing our understanding of craniopharyngiomas and fatigue and the consequences for improving care for patients.”
All persons who have been diagnosed with craniopharyngioma, or their caregivers, are eligible to participate in this registry study.
“We are pleased to join Rhythm in this effort to better understand craniopharyngioma survivors’ experiences with fatigue and factors that may affect it, such as weight gain and daytime sleepiness,” said Amy Wood, Founder and Executive Director of the Raymond A. Wood Foundation.
To participate in the study, please visit www.rawoodfoundation.org/hptumorregistry to enroll into the Hypothalamic-Pituitary Brain Tumors Patient Registry and complete the available surveys. For those who are already enrolled in the registry, please log into your registry account: https://hptumorregistry.iamrare.org/.
For questions related to the study, please contact registry@rawoodfoundation.org.
About the Raymond A. Wood Foundation
The Raymond A. Wood Foundation is a parent and patient-led rare disease patient advocacy organization, dedicated to empowering survivors of craniopharyngioma and hypothalamic-pituitary brain tumors. The mission of the Raymond A. Wood Foundation is to drive research and advocate for treatment outcomes to improve quality of life for hypothalamic-pituitary brain tumor survivors.
About Rhythm Pharmaceuticals
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. The Company develops medicines for previously untreatable or undertreated diseases and provides support for healthcare providers and patients and their families. In collaboration with leading experts across the world, Rhythm is advancing the most comprehensive clinical research program ever initiated in rare melanocortin-4 receptor (MC4R) pathway diseases and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm’s headquarters is in Boston, MA.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the relationship between craniopharyngiomas and fatigue and the potential benefits of a research collaboration with the Raymond A. Wood Foundation. Statements using words such as “expect”, “anticipate”, “believe”, “may”, “will” and similar terms are also forward-looking statements. Such statements are subject to numerous risks, uncertainties and other important factors, including those discussed under the caption “Risk Factors” in Rhythm’s Annual Report on Form 10-K for the year ended December 31, 2024 and other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
Corporate Contact:
David Connolly
Head of Investor Relations and Corporate Communications
Rhythm Pharmaceuticals, Inc.
857-264-4280
dconnolly@rhythmtx.com
Media Contact:
Sheryl Seapy
Real Chemistry
(949) 903-4750
sseapy@realchemistry.com
FAQ
What is the purpose of RYTM's new craniopharyngioma registry study?
Who can participate in Rhythm Pharmaceuticals' craniopharyngioma fatigue study?
How can patients enroll in RYTM's craniopharyngioma fatigue registry?
What is the collaboration between RYTM and Raymond A. Wood Foundation studying?
